PL357674A1 - Kompozycje i sposoby leczenia zaburzeń związanychz hiperlipidemią - Google Patents

Kompozycje i sposoby leczenia zaburzeń związanychz hiperlipidemią

Info

Publication number
PL357674A1
PL357674A1 PL01357674A PL35767401A PL357674A1 PL 357674 A1 PL357674 A1 PL 357674A1 PL 01357674 A PL01357674 A PL 01357674A PL 35767401 A PL35767401 A PL 35767401A PL 357674 A1 PL357674 A1 PL 357674A1
Authority
PL
Poland
Prior art keywords
compositions
methods
treating hyperlipidemic
disorders
hyperlipidemic disorders
Prior art date
Application number
PL01357674A
Other languages
English (en)
Inventor
Thomas Julius Borody
Original Assignee
Thomas Julius Borody
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPQ6969A external-priority patent/AUPQ696900A0/en
Priority claimed from AUPR0851A external-priority patent/AUPR085100A0/en
Application filed by Thomas Julius Borody filed Critical Thomas Julius Borody
Publication of PL357674A1 publication Critical patent/PL357674A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL01357674A 2000-04-19 2001-04-19 Kompozycje i sposoby leczenia zaburzeń związanychz hiperlipidemią PL357674A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ6969A AUPQ696900A0 (en) 2000-04-19 2000-04-19 Novel therapy for hyperlipidaemia-associated disorders
AUPR0851A AUPR085100A0 (en) 2000-10-19 2000-10-19 Novel therapy for hyperlipidaemia-associated disorders

Publications (1)

Publication Number Publication Date
PL357674A1 true PL357674A1 (pl) 2004-07-26

Family

ID=25646303

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01357674A PL357674A1 (pl) 2000-04-19 2001-04-19 Kompozycje i sposoby leczenia zaburzeń związanychz hiperlipidemią

Country Status (10)

Country Link
US (2) US20040009961A1 (pl)
EP (1) EP1284723A4 (pl)
JP (1) JP2003531171A (pl)
AR (1) AR028023A1 (pl)
BR (1) BR0110208A (pl)
CA (1) CA2406067A1 (pl)
MX (1) MXPA02010316A (pl)
NZ (1) NZ522036A (pl)
PL (1) PL357674A1 (pl)
WO (1) WO2001080852A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPS088702A0 (en) 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
EP1388352A1 (en) 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
GB0309154D0 (en) 2003-01-14 2003-05-28 Aventis Pharma Inc Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
US7390504B2 (en) * 2003-11-07 2008-06-24 Jj Pharma, Inc. HDL-boosting combination therapy complexes
JP2008519840A (ja) 2004-11-10 2008-06-12 ジェンザイム・コーポレイション 糖尿病の処置方法
WO2007134086A2 (en) 2006-05-09 2007-11-22 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
EP2594562B1 (en) 2007-05-31 2016-07-20 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
KR101640263B1 (ko) 2007-10-05 2016-07-15 젠자임 코포레이션 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법
JP2011529500A (ja) 2008-07-28 2011-12-08 ジェンザイム コーポレーション 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害
US8309593B2 (en) 2008-10-03 2012-11-13 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
KR101072600B1 (ko) * 2009-04-09 2011-10-11 한올바이오파마주식회사 플루바스타틴을 포함하는 안정한 약제학적 조성물 및 그의 제조방법
KR100980752B1 (ko) * 2009-12-17 2010-09-07 삼일제약주식회사 담체 표면 상에 흡착된 페노피브레이트를 포함하는 과립 및 이를 포함하는 약학 조성물
KR100980749B1 (ko) * 2009-12-17 2010-09-07 삼일제약주식회사 페노피브레이트-함유 과립 및 이를 포함하는 약학 조성물
SG191145A1 (en) 2010-12-13 2013-07-31 Borody Thomas J Gastric and colonic formulations and methods for making and using them
MX353660B (es) 2011-11-30 2018-01-23 Dae Woong Pharma Composicion farmaceutica para evitar o tratar hiperlipidemia.
WO2013169648A1 (en) 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
WO2014016671A2 (en) 2012-07-27 2014-01-30 Redhill Biopharma Ltd. Formulations and methods of manufacturing formulations for use in colonic evacuation
TN2017000344A1 (en) * 2015-02-06 2019-01-16 Intercept Pharmaceuticals Inc Pharmaceutical compositions for combination therapy
CN119033748B (zh) * 2024-08-21 2025-08-01 南方医科大学南方医院 环丙贝特在制备抗乙型肝炎病毒的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2924562C3 (de) * 1979-06-19 1982-04-29 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Lipide senkendes Arzneimittel
GB9013448D0 (en) * 1990-06-15 1990-08-08 Sandoz Ltd Pharmaceutical resorption-improved somatostatin compositions,their preparation and use
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
IT1245890B (it) * 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
US5763435A (en) * 1995-11-21 1998-06-09 Children's Hospital Medical Center Sulfate conjugates of ursodeoxycholic acid, and their beneficial use in inflammatory disorders
CN1342091A (zh) * 1998-12-23 2002-03-27 G.D.瑟尔有限公司 心血管指征的联合用药
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6458383B2 (en) * 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin

Also Published As

Publication number Publication date
US20080286354A1 (en) 2008-11-20
MXPA02010316A (es) 2005-04-19
JP2003531171A (ja) 2003-10-21
NZ522036A (en) 2004-04-30
BR0110208A (pt) 2003-01-28
AR028023A1 (es) 2003-04-23
CA2406067A1 (en) 2001-11-01
EP1284723A4 (en) 2004-06-30
WO2001080852A1 (en) 2001-11-01
US20040009961A1 (en) 2004-01-15
EP1284723A1 (en) 2003-02-26

Similar Documents

Publication Publication Date Title
ATE323661T1 (de) Behandlung von mineralischen stoffen
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
NO20011121D0 (no) FremgangsmÕte for formasjonsbehandling med deformerbare partikler
EP1438054A4 (en) METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS USING MODIFIED NUCLEOSIDE AT 4 'POSITION
ATE306481T1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE411332T1 (de) 3'-prodrugs von 2'-deoxy-beta-l-nukleosiden
DE60019195D1 (de) Behandlung durch Ablation von Knochenmetastasen
NO20024610D0 (no) Synergistiske metoder og blandinger for behandling av kreft
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
AU2002364364A8 (en) Method of treating apoptosis and compositions thereof
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE265860T1 (de) Impstoff zur behandlung von atherosclerosis
FIU20060389U0 (fi) Luusairauksien hoito
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE415163T1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE60103685D1 (de) Behandlung von Poriomania
NO20024236D0 (no) Behandling av psoriasis
DE60110748D1 (de) Behandlung von fluorkohlenstoff-beschickungen
NO20032156D0 (no) Behandling av angstforstyrrelser
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
DE60105053D1 (de) Zusammensetzungen zur behandlung von gewebe
DE60139151D1 (de) Haarwuchshemmer und diese enthaltende zusammensetzungen

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)